文 献 9）Cheng Y, Wang CY, Li ZR, Pan Y, Liu MB, Jiao Z . C a n p o p u l a t i o n p h a r m a c o k i n e t i c s o f antibiotics be extrapolated? Implications of external evaluations. Clin Pharmacokinet 2021; 60: 53-68. 10）Itohara K, Yamamoto K, Fujinaka S, Hashimoto M, Tamura N, Kitahiro Y, et al. Pharmacokinetic and pharmacodynamic assessment of valganciclovir in infants with congenital cytomegalovirus infection. Ther Drug Monit 2025; 47: 393-9.11）Nguyen T, Oualha M, Briand C, Bendavid M, Béranger A, Benaboud S, et al. Population pharmacokinetics of intravenous ganciclovir and oral valganciclovir in a pediatric population to optimize dosing regimens. Antimicrob Agents Chemother 2021; 65: e02254-20.12）Jorga K, Chavanne C, Frey N, Lave T, Lukacova V, Parrott N, et al. Bottom-up meets top-down: c o m p l e m e n t a r y p h y s i o l o g i c a l l y b a s e d pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children. Clin Pharmacol Ther 2016; 100 :761-9. 13）Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci 2013; 102: 2941-52.14）Iwata KI, Torii Y, Fukuda Y, Haruta K, Yamaguchi M, Suzuki T, et al. Associations of nucleoside diphosphate-linked moiety X-type motif 15 variants with neutropenia during antiviral therapy for cytomegalovirus disease in pediatric liver transplant recipients. Transpl Infect Dis 2025; 27: e70079.症候性先天性サイトメガロウイルス感染症におけるバルガンシクロビルのPK-PD解析11[https://www.cfa.go.jp/policies/boshihoken/r5-nyuuyoujityousa(accessed 2025-9-6)] 1）Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A , A r a v - B o g e r R , M i c h a e l s M G , e t a l . Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372: 933-43. 2）Kawamura A, Abe S, Shirai K, Masuda Y, Imagawa Y, Nakata Y, et al. Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection. Biomedicines 2025; 13: 1739. 3）Nishikawa JK, Aban I, Acosta EP, Sánchez PJ, Kimberlin DW. Examining neutropenia during treatment of cytomegalovirus disease in neonates. Pediatr Infect Dis J 2025; 44: 759-63. 4）Acosta EP, Brundage RC, King JR, Sánchez PJ, Sood S, Agrawal V, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007; 81: 867-72. 5）Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr 1979; 95: 89-98. 6）Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-21. 7）Yoshida SH, Unno N, Kagawa H, Shinozuka N, Kozuma S, Taketani Y. Sonographic determination of fetal size from 20 weeks of gestation onward correlates with birth weight. J Obstet Gynaecol Res 2001; 27: 205-11. 8）こども家庭庁「令和５年乳幼児身体発育調査」
元のページ ../index.html#25